Novartis to Acquire Tourmaline Bio to Strengthen Cardiovascular Pipeline

Novartis plans to acquire Tourmaline Bio for approximately USD 1.4 billion, gaining access to the Phase 3 ready asset pacibekitug, an anti-IL-6 monoclonal antibody targeting systemic inflammation in atherosclerotic cardiovascular disease, which shows promising results in reducing inflammation markers and addresses an unmet need in cardiovascular risk reduction.